Fig. 4
Plasma concentrations of L59 LAP-DPs in CCl4-treated mice. a Plasma concentrations of L59 LAP-DPs, as well as hepatic HDP contents, in CCl4-treated mice (N = 7–8) were measured. b The expression levels of αSMA mRNA in the liver tissues from CCl4-treated mice (N = 7–8) were determined. c–e The scatter plots between the plasma concentration of L59 LAP-DPs (a) and expression level of αSMA mRNA (b) in each mouse at 4 weeks (c), 8 weeks (d), and 12 weeks (e) after starting CCl4 treatment. f Immunostaining of liver sections from mice (N = 7–8) treated with CCl4 for 4 weeks. Fibrotic regions were stained by picro-sirius red (left panels). Their proximal sections were immunostained with anti-αSMA (middle panels) and R58 antibodies (right panels). Representative areas from two randomly selected mice were shown *p-value <0.05, **p-value <0.01, ***p-value <0.001 obtained comparing to control value